UNSPSC 51341903: Efavirenz

This classification denotes a reverse transcriptase inhibitor with the molecular formula C14H9ClF3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JE6H2O27P8, chemically known as 2h-3,1-benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4s)- but generally known as efavirenz, which bears US NIH Compound Identifier 64139. European Medicines Agency schedules Efavirenz in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06463MIG.

UNSPSC 51341903 Efavirenz, a Commodity code, nominally identifies a specific antiretroviral pharmaceutical, but recent state and local solicitations tagged with this code show little activity directly aligned with efavirenz procurement itself. Instead, the recent opportunities reveal a broader pattern of state and local health agencies and purchasing collaboratives acquiring generic pharmaceuticals, over-the-counter products, emergency medical supplies, and naloxone through competitive bidding and cooperative purchasing vehicles. The issuing bodies include state health and human services departments (Texas HHS Commission), county public health agencies (Seminole County, Florida), municipalities (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The scope of work spans fixed-price pharmaceutical supply contracts with authorized wholesalers, emergency response medical consumables for fire rescue divisions, direct-to-manufacturer prescription programs, and naloxone distribution for community health initiatives.

Recent opportunities show activity concentrated in Florida, Texas, and Minnesota, with MMCAP's cooperative framework spanning multiple states including Oregon. Representative solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, response due April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs; City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, estimated at $700,000 and designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products with wholesalers effective July 1, 2026. The code shows limited direct relevance to efavirenz-specific procurement in the recent opportunities reviewed.